No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ANVS240517P10000
- 1.70
- -0.25-12.82%
15min DelayClose May 17 15:59 ET
2.70High1.70Low
2.70Open1.95Pre Close1.54K Volume1.91K Open Interest10.00Strike Price297.99KTurnover2845.28%IV-2.83%PremiumMay 17, 2024Expiry Date1.69Intrinsic Value100Multiplier0DDays to Expiry0.01Time Value100Contract SizeAmericanOptions Type-0.7617Delta0.1659Gamma4.32Leverage Ratio-12.8047Theta0.0000Rho-3.29Eff Leverage0.0002Vega
Intraday
- 5D
- 1D
News
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Biocryst Pharmaceuticals, T2 Biosystems, Annovis Bio Among Healthcare Movers
Buy Rating Maintained for Annovis Bio Ahead of Key Parkinson's Drug Trial Results
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Stocks With More Than 10% Short Interest - Finviz Screener
Express News | Annovis Bio Shares Are Trading Higher After the Company Reported Better-than-expected Q1 GAAP EPS Results
Comments
3
1
GL to all$Annovis Bio(ANVS.US$ News that the FDA is going to clear their drug. Ran out of shares today. Borrow rate is higher than its ever been. Price movement is indicating reversal. Only 3 resistance points which are 6.20, 6.89, and 7.28.
3
$Annovis Bio(ANVS.US$ Reuters· just
Annovis Bio - Believe FDA Will Accept Buntanetap for Symptomatic Relief,Will Allow to Continue Next Pivotal Phase III Study for Disease-Modification
Annovis Bio - Believe FDA Will Accept Buntanetap for Symptomatic Relief,Will Allow to Continue Next Pivotal Phase III Study for Disease-Modification
1
2
Read more